FAQ

indium In 111 ibritumomab tiuxetan

Known as: In 111 Ibritumomab Tiuxetan, In111 ibritumomab tiuxetan, Indium In-111 Ibritumomab Tiuxetan 
A radiolabeled monoclonal antibody that is used to detect certain types of B-cell non-Hodgkin lymphoma and is being studied in the detection of other… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2018
0102020002018

Related topics

Related topics

2 relations
IDEC-In2B8/rituximabIDEC-In2B8/rituximab/yttrium Y 90 ibritumomab tiuxetan

Related mentions per year

Related mentions per year

1999-2018
1990200020102020
indium In 111 ibritumomab tiuxetan
IDEC-In2B8/rituximab/yttrium Y 90 ibritumomab tiuxetan
IDEC-In2B8/rituximab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Marketed therapeutic antibodies compendium
Therapeutic monoclonal antibodies (mAbs) are currently being approved for marketing in Europe and the United States, as well as… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
PURPOSE We conducted an international, randomized, phase III trial to evaluate the efficacy and safety of consolidation with… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
PURPOSE This phase II trial evaluated the safety and efficacy of combining yttrium-90 (90Y) ibritumomab tiuxetan with high-dose… (More)
Is this relevant?
2007
2007
Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma.
BACKGROUND Therapeutic options for refractory or recurrent primary central nervous system lymphoma (PCNSL) are limited. The blood… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation.
A prospective, multicenter, nonrandomized phase 2 trial was conducted to evaluate the efficacy and safety of a single dose of… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk…
We conducted a phase 1/2 trial of high-dose 90Y-ibritumomab tiuxetan in combination with high-dose etoposide (VP-16) 40 to 60 mg… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 4
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study.
We previously demonstrated that yttrium-90 (Y-90) ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) was safe and effective… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
UNLABELLED Ibritumomab tiuxetan is an anti-CD20 murine IgG1 kappa monoclonal antibody (ibritumomab) conjugated to the linker… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
PURPOSE Rituximab is commonly used as a single agent or in combination therapy for non-Hodgkin's lymphoma (NHL). Ibritumomab… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.
Mildly thrombocytopenic patients with relapsed or refractory low-grade non-Hodgkin lymphoma (NHL) have an increased risk of… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 5
Is this relevant?